Program
Pneumococcal 20-Valent Conjugate Vaccine
Also written as “20vPnC”, “20-valent pneumococcal conjugate vaccine” and “Prevnar 20”.
Its studies are mostly in Pneumococcal Infections · Pneumonia, Pneumococcal · Respiratory Syncytial Virus Infections, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 183 open or running | phase 3since Nov 29, 2018 | Nov 29, 2018 | Jun 10, 2027phase 1 · NCT07023081 |
| GlaxoSmithKline | 20 open or running | phase 3since May 18, 2023 | Jun 3, 2022 | none ahead |
| LiteVax BV | 11 open or running | phase 1since Mar 30, 2025 | Mar 30, 2025 | none ahead |
| Merck | 11 open or running | phase 1since Dec 10, 2025 | Dec 10, 2025 | Oct 24, 2028phase 1 · NCT07300267 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 3 studies since Nov 29, 2018.
- May 6, 20202 phase 3 studies in Pneumococcal InfectionsPfizer · NCT04379713, NCT04382326
- Aug 21, 20203 phase 3 studies in Pneumococcal InfectionsPfizer · NCT04546425, NCT04526574, NCT04530838
- Nov 18, 2020Phase 3 study in Pneumococcal InfectionsPfizer · NCT04642079 · 839 enrolled · United States
- May 3, 20212 phase 3 studies in Pneumococcal InfectionsPfizer · NCT04875533, NCT04887948
- Jun 1, 2022Phase 3 study in Pneumococcal InfectionsPfizer · NCT05408429 · 356 enrolled · Hungary, Poland, Spain
- Jun 3, 2022GlaxoSmithKline’s first study: phase 2 study in Pneumonia, BacterialNew to GlaxoSmithKlineGlaxoSmithKline · NCT05412030 · 388 enrolled · United States, Puerto Rico
- Aug 22, 2022Phase 3 study in Pneumococcal InfectionsPfizer · NCT05512819 · 541 enrolled · India, Taiwan
- May 16, 2023Phase 3 study in Pneumococcal InfectionsPfizer · NCT05875727 · 405 enrolled · India
- May 18, 2023Phase 3 study in Respiratory Syncytial Virus InfectionsGlaxoSmithKline · NCT05879107 · 1,113 enrolled · United States, Belgium, Poland and more
- Mar 30, 2025LiteVax BV’s first study: phase 1 study in Vaccine ReactionNew to LiteVax BVLiteVax BV · NCT06986239 · 80 planned
- Jun 5, 20252 phase 1 studies in Pneumococcal InfectionsPfizer · NCT07019909, NCT07023081
- Aug 14, 2025Phase 3 study in HealthyPfizer · NCT07160244 · 6,000 planned · United States, Argentina, Brazil and more
- Dec 10, 2025Merck’s first study: phase 1 study in Pneumococcal InfectionsNew to MerckMerck · NCT07300267 · 210 planned · United States
- Jul 24, 2026Phase 3 study in Pneumococcal InfectionsPfizer · NCT07754539 · 1,250 planned · China
Ahead
- Jun 10, 2027Primary completion: phase 1 study in Pneumococcal InfectionsPfizer · NCT07023081
- Oct 24, 2028Primary completion: phase 1 study in Pneumococcal InfectionsMerck · NCT07300267
- Nov 6, 2028Primary completion: phase 3 study in HealthyPfizer · NCT07160244
- Nov 30, 2028Primary completion: phase 3 study in Pneumococcal InfectionsPfizer · NCT07754539
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“A pneumococcal conjugate vaccine containing 20 different strains of the bacterium Streptococcus pneumoniae, that is used for the prevention of pneumococcal disease”NCIt, by rule
“Pneumococcal 20-Valent Conjugate Vaccine”name, by rule
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07754539Pneumococcal Infections · China | 3 | Recruiting | Pfizer | Nov 30, 2028 | 1,250 |
| NCT07300267Pneumococcal Infections · United States | 1 | Recruiting | Merck | Oct 24, 2028 | 210 |
| NCT07160244Healthy · United States, Argentina, Brazil and more | 3 | Recruiting | Pfizer | Nov 6, 2028 | 6,000 |
| NCT07023081Pneumococcal Infections · China | 1 | Active, not recruiting | Pfizer | Jun 10, 2027 | 200 |
| NCT07019909Pneumococcal Infections · China | 1 | Completed | Pfizer | Jan 28, 2026 | 400 |
| NCT06986239Vaccine Reaction | 1 | Not yet recruiting | LiteVax BV | Apr 1, 2026 | 80 |
| NCT05879107Respiratory Syncytial Virus Infections · United States, Belgium, Poland and more | 3 | Completed | GlaxoSmithKline | Dec 6, 2023 | 1,113 |
| NCT05875727Pneumococcal Infections · India | 3 | Completed | Pfizer | Oct 2, 2023 | 405 |
| NCT05512819Pneumococcal Infections · India, Taiwan | 3 | Completed | Pfizer | Sep 20, 2025 | 541 |
| NCT05412030Pneumonia, Bacterial · United States, Puerto Rico | 2 | Completed | GlaxoSmithKline | Sep 18, 2025 | 388 |
| NCT05408429Pneumococcal Infections · Hungary, Poland, Spain | 3 | Completed | Pfizer | Jun 1, 2023 | 356 |
| NCT04887948Pneumococcal Infections · United States | 3 | Completed | Pfizer | Dec 8, 2021 | 570 |
| NCT04875533Pneumococcal Infections · Japan, Korea, Republic of, Taiwan | 3 | Completed | Pfizer | May 13, 2022 | 1,425 |
| NCT04642079Pneumococcal Infections · United States | 3 | Completed | Pfizer | Apr 6, 2022 | 839 |
| NCT04530838Pneumococcal Infections · Japan | 3 | Completed | Pfizer | Apr 2, 2022 | 668 |
| NCT04546425Pneumococcal Infections · Australia, Belgium, Czechia and more | 3 | Completed | Pfizer | Apr 22, 2022 | 1,258 |
| NCT04526574Pneumococcal Infections · United States | 3 | Completed | Pfizer | Jun 29, 2021 | 1,796 |
| NCT04382326Pneumococcal Infections · United States, Puerto Rico | 3 | Completed | Pfizer | Sep 2, 2022 | 1,997 |
| NCT04379713Pneumococcal Infections · United States, Argentina, Canada and more | 3 | Completed | Pfizer | Aug 31, 2022 | 1,511 |
| NCT03835975Pneumococcal Infections · United States, Sweden | 3 | Completed | Pfizer | Feb 12, 2020 | 875 |
| NCT03828617Pneumococcal Infections · United States | 3 | Completed | Pfizer | Oct 9, 2019 | 1,710 |
| NCT03760146Pneumococcal Infections · United States, Sweden | 3 | Completed | Pfizer | Dec 16, 2019 | 3,902 |
How it is read
Names in the registry
- “20vPnC”, 10 entries
- “20-valent pneumococcal conjugate vaccine”, 7 entries
- “Prevnar 20”, 2 entries
- “PCV20 (Stage 1)”, 1 entry
- “PCV20 (Stage 2)”, 1 entry
Conditions, from the studies’ own filings
- Pneumococcal Infections, 18 studies
- Pneumonia, Pneumococcal, 1 study
- Respiratory Syncytial Virus Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.